Trial Profile
A prospective multicenter open-label randomized study to assess efficacy and safety of everolimus in combination with cyclosporine microemulsion versus everolimus without calcineurine inhibitor in combination with EC-MPS [enteric coated-mycophenolate sodium], in adult renal transplant patients in maintenance
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Mycophenolate sodium (Primary) ; Ciclosporin; Corticosteroids
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Sponsors Novartis
- 15 Aug 2010 Primary endpoint 'Glomerular filtration rate' has been met.
- 15 Aug 2010 Results presented at the 23rd International Congress of the Transplantation Society.
- 16 Feb 2007 New trial record.